These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23527295)

  • 41. Models for predicting effective HIV chemoprevention in women.
    Nicol MR; Emerson CW; Prince HM; Nelson JA; Fedoriw Y; Sykes C; Geller EJ; Patterson KB; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2015 Apr; 68(4):369-76. PubMed ID: 25501616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
    Painter GR; Almond MR; Trost LC; Lampert BM; Neyts J; De Clercq E; Korba BE; Aldern KA; Beadle JR; Hostetler KY
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3505-9. PubMed ID: 17646420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
    Sepúlveda-Crespo D; Sánchez-Rodríguez J; Serramía MJ; Gómez R; De La Mata FJ; Jiménez JL; Muñoz-Fernández MÁ
    Nanomedicine (Lond); 2015; 10(6):899-914. PubMed ID: 25867856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical development of microbicides for the prevention of HIV infection.
    D'Cruz OJ; Uckun FM
    Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies.
    Jacot TA; Nelson A; Thurman A; Kashuba AD; Archer DF; Doncel GF
    PLoS One; 2014; 9(12):e114368. PubMed ID: 25489736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.
    Anderson PL; Glidden DV; Bushman LR; Heneine W; García-Lerma JG
    J Antimicrob Chemother; 2014 Sep; 69(9):2470-6. PubMed ID: 24862094
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Considerations regarding antiretroviral chemoprophylaxis in MSM.
    Poynten IM; Zablotska I; Grulich AE
    Curr Opin HIV AIDS; 2012 Nov; 7(6):549-56. PubMed ID: 22918448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
    de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Topical microbicides--what's new?
    Karim QA; Baxter C; Karim SA
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2():S144-9. PubMed ID: 23764627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.
    Wei X; Hunt G; Abdool Karim SS; Naranbhai V; Sibeko S; Abdool Karim Q; Li JF; Kashuba AD; Werner L; Passmore JA; Morris L; Heneine W; Johnson JA
    J Infect Dis; 2014 Jun; 209(12):1916-20. PubMed ID: 24436453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV preexposure prophylaxis: new data and potential use.
    Celum CL
    Top Antivir Med; 2011 Dec; 19(5):181-5. PubMed ID: 22298887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.
    Yang KH; Hendrix C; Bumpus N; Elliott J; Tanner K; Mauck C; Cranston R; McGowan I; Richardson-Harman N; Anton PA; Kashuba AD
    PLoS One; 2014; 9(10):e106196. PubMed ID: 25350119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
    Mansoor LE; Abdool Karim Q; Mngadi KT; Dlamini S; Montague C; Nkomonde N; Mvandaba N; Baxter C; Gengiah TN; Samsunder N; Dawood H; Grobler A; Frohlich JA; Abdool Karim SS
    Trials; 2014 Dec; 15():496. PubMed ID: 25527071
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
    Celum C; Baeten JM
    Curr Opin Infect Dis; 2012 Feb; 25(1):51-7. PubMed ID: 22156901
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice.
    Berges BK; Akkina SR; Folkvord JM; Connick E; Akkina R
    Virology; 2008 Apr; 373(2):342-51. PubMed ID: 18207484
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
    Landman R; Koulla-Shiro S; Sow PS; Ngolle M; Diallo MB; Guèye NF; Le Moing V; Eymard-Duvernay S; Benalycherif A; Charpentier C; Peytavin G; Delaporte E; Girard PM;
    Antivir Ther; 2014; 19(1):51-9. PubMed ID: 23970206
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
    Francisci D; Falcinelli E; Belfiori B; Petito E; Fierro T; Baldelli F; Gresele P
    AIDS Patient Care STDS; 2011 Oct; 25(10):567-9. PubMed ID: 21851265
    [No Abstract]   [Full Text] [Related]  

  • 60. An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
    McGowan I
    Am J Reprod Immunol; 2014 Jun; 71(6):624-30. PubMed ID: 24635047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.